Journal
AIDS RESEARCH AND HUMAN RETROVIRUSES
Volume 35, Issue 1, Pages 25-32Publisher
MARY ANN LIEBERT, INC
DOI: 10.1089/aid.2018.0161
Keywords
HIV-1 pathogenesis; type 1 interferon; immune activation; persistent latent reservoir
Categories
Funding
- NIAID NIH HHS [P30 AI094189] Funding Source: Medline
- NIDA NIH HHS [R01 DA016078] Funding Source: Medline
Ask authors/readers for more resources
HIV-1 remains a chronic viral infection of global health importance. Although HIV-1 replication can be controlled by antiretroviral therapy (ART), there is no cure due to persistence of a long-lived latent reservoir. In addition, people living with HIV-1 who are taking ART still bear signatures of persistent immune activation that include continued type 1 interferon (IFN) signaling. Paradoxically, type 1 IFN exerts a limited role on the control of chronic HIV-1. Indeed, recent reports from humanized mice suggest that type 1 IFN may partly maintain the latent reservoir. In this review, we discuss the molecular interactions between HIV-1 and the type 1 IFN signaling pathway, and examine the efficacy of type 1 IFNs in vivo. We also explore whether limited type 1 IFN manipulation may have a therapeutic role.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available